Agios Pharmaceuticals
AGIO
161 hedge funds and large institutions have $1.63B invested in Agios Pharmaceuticals in 2016 Q4 according to their latest regulatory filings, with 23 funds opening new positions, 63 increasing their positions, 49 reducing their positions, and 24 closing their positions.
198% more call options, than puts
Call options by funds: $39M | Put options by funds: $13.1M
92.87% more ownership
Funds ownership: 0% → 92.87% (+93%)
29% more repeat investments, than reductions
Existing positions increased: 63 | Existing positions reduced: 49
4% less first-time investments, than exits
New positions opened: 23 | Existing positions closed: 24
1% less funds holding
Funds holding: 163 → 161 (-2)
14% less funds holding in top 10
Funds holding in top 10: 7 → 6 (-1)
18% less capital invested
Capital invested by funds: $1.99B → $1.63B (-$364M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital International Investors
Los Angeles,
California
|
+$67.8M |
| 2 |
AG
Artal Group
Luxembourg
|
+$18.4M |
| 3 |
CGT
Capital Guardian Trust
Los Angeles,
California
|
+$9.24M |
| 4 |
BIT
BlackRock Institutional Trust
San Francisco,
California
|
+$9.06M |
| 5 |
BB
BB Biotech
Schaffhausen,
Switzerland
|
+$8.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
-$18.2M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$13.7M |
| 3 |
Balyasny Asset Management
Chicago,
Illinois
|
-$12.4M |
| 4 |
BA
BlackRock Advisors
Wilmington,
Delaware
|
-$9.61M |
| 5 |
EC
EcoR1 Capital
San Francisco,
California
|
-$9.27M |
AGIO Hedge Fund Activity: Q4 2016 in Review
161 of the 4,000 institutional investors tracked by Wall St. Rank reported a position in Agios Pharmaceuticals (AGIO) for Q4 2016, worth a combined $1.63B — down 18% from $1.99B a quarter earlier.
Sellers outnumbered buyers: 24 funds closed out of AGIO and 23 opened new positions — a net loss of 1 holder — while 49 trimmed existing stakes and 63 added.
The largest buyer was Capital International Investors, adding an estimated $67.8M. The largest seller was Lord, Abbett & Co, cutting an estimated $18.2M.
- 161 institutional investors held Agios Pharmaceuticals (AGIO) as of Q4 2016, down from 163 in Q3 2016.
- Funds reported $1.63B of Agios Pharmaceuticals stock for Q4 2016, down 18% quarter-over-quarter.
- 23 funds opened new Agios Pharmaceuticals positions in Q4 2016 and 24 closed out, a net change of -1 holder.
- The largest Agios Pharmaceuticals buyer in Q4 2016 was Capital International Investors, an estimated $67.8M added.
- The largest Agios Pharmaceuticals seller in Q4 2016 was Lord, Abbett & Co, an estimated $18.2M sold.
Based on aggregated 13F filings for Q4 2016.